CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke
Release Date: 01/30/2026
April 20, 2026 Capitol Hill Report: Neuroscience Research in FY2027
Neurology Minute
In this episode, Dr. Jason Crowell discusses the Capitol Hill Report from April 20th, which provides updates on federal funding for neuroscience research in fiscal year 2027 (FY2027). Stay updated with what’s happening on the hill by visiting . Learn how you can get involved with .
info_outline
Navigating the Residency Application Process: Key Takeaways for Aspiring Neurologists
Neurology Minute
Casey Kozak discusses the process of applying to neurology residency. This episode offers insights for applicants and for neurologists who guide and mentor the next generation of neurologists.
info_outline
Trends in Head CT Use in US Emergency Department Patients
Neurology Minute
Dr. Andy Southerland and Dr. Layne Dylla discuss the trends in head CT use in US emergency departments from 2007 to 2022, highlighting disparities, regional variations, and the potential role of AI in optimizing imaging decisions. Show citations: Dylla L, Krothapalli N, Tu L, et al. Trends in Head CT Use in US Emergency Department Patients From 2007 to 2022: A Nationwide Analysis. Neurology. 2025;105(12):e214347. doi:
info_outline
A Discussion with Dr. Alison Christy: 2026 Ted Burns Humanism in Neurology Award Winner
Neurology Minute
Dr. Stacey Clardy talks with Dr. Alison Christy, the recipient of the 2026 Ted Burns Humanism in Neurology Award, about her inspiring career, innovative approaches to neurology education, and how she fosters compassion and creativity in medicine.
info_outline
Global Burden of Headache Disorders in Older Adults (Aged ≥ 55 Years) from 1990-2021
Neurology Minute
Dr. Tesha Monteith talks with Ayesha Sohail about her abstract titled "Global Burden of Headache Disorders in Older Adults (Aged ≥ 55 Years) from 1990-2021: An Analysis of Epidemiology, Trends, and Socioeconomic Disparities." Read more about this abstract on the .
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 3
Neurology Minute
In the final episode of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the study results and their implications for improving clinical practice. Read more about this abstract on the .
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 2
Neurology Minute
In part two of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss how this technology was developed and how it has evolved. Read more about this abstract on the .
info_outline
2026 AAN President's Award Recipient - Dr. Walter J. Koroshetz
Neurology Minute
Dr. Greg Cooper talks with Dr. Walter J. Koroshetz about his advice for early neurologists. Read more about the .
info_outline
A Path to Preventing Cognitive Impairment Due to Alzheimer's Disease
Neurology Minute
Dr. Greg Cooper and Dr. Eric Reiman discuss emerging antibody therapies for preclinical Alzheimer's disease and the clinical, regulatory, and equity considerations shaping prevention trials and future care. Show citation: Reiman EM, Alexander RC, Langbaum JB, et al. A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA. Lancet Neurol. 2026;25(3):268-278. doi:
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 1
Neurology Minute
In the first part of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the background and evolving terminology around circulating tumor DNA, cell‑free DNA and CSF‑based testing in neurology. Read more about this abstract on the .
info_outlineDr. Tesha Monteith and Dr. Michael Eller discuss the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke.
Show citation:
Eller MT, Schwarzová K, Gufler L, et al. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. Neurology. 2025;105(2):e213852. doi:10.1212/WNL.0000000000213852
Show transcript:
Dr. Tesha Monteith:
Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Michael Eller from the Department of Neurology Medical University of Innsbruck, Austria on the neurology podcast on his paper, CGRP Targeted Migraine Therapies in Patients with Vascular Risk Factors or Stroke: A Review.
Hi, Michael.
Dr. Michael Eller:
Hello.
Dr. Tesha Monteith:
Why don't you summarize your general approach to use of CGRP targeted therapies in patients that might be at risk for vascular events when considering safety?
Dr. Michael Eller:
Yeah. About acute vascular events, we should stop CGLP targeted drugs immediately. When we come to post-stroke, we should reassess the necessity of these targeted treatments after recovery. We suggest a minimum of three months pause after ischemic stroke to allow early recovery and remodeling, and then restart only after individualized benefit risk review.
In high-risk primary prevention, so no stroke yet, but elevated risk, if the patients are 65 years or older with established cardiovascular disease, we should prefer traditional preventives. And if CGLP targeted therapy is essential, we should consider Gepants cautiously due to their shorter half lives.
We should avoid CGLP targeted treatments in small vessel disease, distal stenosis, Raynaud's phenomenon, and uncontrolled hypertension. For acute migraine treatment, we can consider gepants or ditans as alternatives to triptans and NSAIDs in relevant stroke risk or post-stroke patients, individualized to comorbidities.
Dr. Tesha Monteith:
Great.
And we should say that the label updates include hypertension and Raynaud's phenomenon as potential vascular complications. Otherwise, these are more theoretical risks based on what we know about CGRP.
Dr. Michael Eller:
Yes, I totally agree because large studies did not show any elevated cardiovascular risk signals. And for post-marketing databases, we did not see any elevated cardiovascular risk so far. However, in pre-clinical settings, studies showed large infarct size in pretreated mice.
Dr. Tesha Monteith:
Great. Well, thank you again for doing this work. It was a phenomenal read and congratulations.
Dr. Michael Eller:
Thank you.
Dr. Tesha Monteith:
This is Tesha Monteith. Thank you for listening to the Neurology Minute.